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INTRODUCTION 
 
Synovial sarcoma is an unusual malignant tumour, derived from soft tissue mesenchymal 
cells. It arises most commonly in the deep soft tissues of lower extremities, especially in the 
region of the lower thigh, with a predilection for sites in proximity to large joints, such as 
the knee and ankle (Shmookler et al., 1982; Miloro et al., 1994). The peak incidence is in 
adolescents and young adults between 16 and 49 years of age (median 34 years), and the 
tumour affects males more often than females (Shmookler et al., 1982). Synovial sarcoma 
represents approximately 5-10% of all soft tissue sarcomas, only 3% of which occur in the 
head and neck region (Kartha and Bumpous, 2002). The most common site is the 
hypopharynx, with the larynx being the least common site (Dei Tos et al., 1998). 
Primary synovial sarcoma of the parotid gland is exceptionally uncommon, with few cases 
reported in the literature (Amble et al., 1992). In cases with adequate clinical 
documentation, tumours present as painless masses and mostly in the parotid gland of 
young and middle-aged men (Amble et al., 1992). Diagnostic methods are clinical 
examination, CT or MR imaging, and histological examination. Therapy included primary 
surgical wide excision with elective neck dissection. The tumour is moderately sensitive to 
chemotherapy and radiotherapy, and these treatment modalities may prove useful as 
adjunctive therapy (Shmookler et al., 1982). The prognosis depends on the size and grade of 
the tumor (Thompson et al., 2000). 
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CASE REPORT 
 
A 15-year-old boy with a painless swelling in the right parotid gland was previously 
examined by the paediatrician and referred for further treatment. The patient's medical 
history was unremarkable and his general condition was good. Clinical examination 
revealed a nonmobile mass on the right side of his face, in the front of ear, about 4 cm in 
diameter, of solid consistency, and with clinically negative neck. The patient did not 
complain of any pain or neurological deficit in the facial region. Opening of the mouth was 
not restricted and functions of the facial nerve were completely normal. Results of routine 
laboratory tests were within normal limits. Cytological analyses (FNA) of the mass pointed 
to a tumour of mesenchymal origin. MR imaging with contrast showed an expansile mass 
in the deep lobe of the right parotid gland with infiltration of the superficial lobe without 
evidence of metastatic lymphadenopathy (Fig. 1 and 2). The first step of therapy was a 
surgical procedure, including wide excision and total parotidectomy with selective neck 
dissection (levels II, III and Va). 
 
Histopathological findings: 
The surgical specimen consisted of the parotid gland and lymph nodes from the selective 
neck dissection (Fig. 3). A multinodular, well-demarcated, rubbery, gray-white tumour, 
measuring 4 cm in diameter at its widest, presented within the parotid gland. Microscopic 
analysis revealed highly cellular whirling fascicles of spindle-shaped cells with uniform, 
oval, vesicular, dark-staining nuclei and indistinct cytoplasm (Fig. 4). The cellular portions 
alternated with acellular hyalinized collagen bands. The central portion of the largest 
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tumour nodule contained ill-defined myxoid areas. Mitotic activity was moderate (3-5 
mitotic figures per 10 high-power fields). Tumour cells revealed diffusely and strongly 
positive immunostaining for vimentin, calponin, bcl-2 and Ki67 (>50%), weakly positive 
staining for S100 and smooth-muscle actin and negative staining for pancytokeratin, CK7, 
EMA and desmin (Fig. 5). RT-PCR analysis revealed positive SYT/SSX1 and SYT/SSX2 
translocations. The definitive histopathological diagnosis was synovial sarcoma of 
monophasic type with clear margins. 
In the specimen after selective neck dissection of levels II, III and Va, 15 lymph nodes were 
examined, all of which were histological negative. 
 
Following consultation with a paediatric oncologist, the next step in treatment were 9 
cycles of ifosfamide- based chemotherapy (CWS protocol - high risk group). After 
chemotherapy, radiotherapy followed in 30 dosages applying a total of 60 Gy. 
Two years later, the condition of the patient is generally good, the surgical area has healed 
without complications, the patient is free of loco-regional recurrence and distant metastasis, 
and the control MRI of the head, neck and chest was negative for any evidence of 
neoplastic disease. 
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DISCUSSION 
 
Synovial sarcoma is a rare tumour, classified as a soft tissue sarcoma. The origin of these 
tumours is believed to be from an undifferentiated mesenchymal cell that undergoes 
synovioblastic differentation (Barnes, 2001; Grayson et al., 1998). Despite its name, 
synovial sarcoma is not restricted to periarticular sites (Goebel et al., 2004). Three percent 
of cases arise in the head and neck region (Kartha and Bumpous, 2002). Because of the 
rarity of the neoplasm in the head and neck region the possibility of misdiagnosis is a likely 
event. The most common site in the head and neck is the hypopharynx, with the larynx 
being the least common site (Dei Tos et al., 1998). In the neck, they typically occur at the 
level of the bifurcation of the carotid artery, intimately associated with the prevertebral 
fascia (Barnes, 2001). Synovial sarcomas have been detected on unusual sites in the oral 
and maxillofacial region such as cheek mucosa (Goebel et al., 2004), maxillary sinus (Sun 
et al., 2003), mandible (Tilakaratne, 2006), tongue (Guzmán Patraca et al., 1975;  Carrillo 
et al., 1992), floor of the mouth (Meer et al., 2003), soft palate (Massarelli et al., 1978), and 
parotid gland (Grayson et al., 1998; Jay et al., 2008; Barkan and El-Naggar, 2004; Cho et 
al., 2008). Similarly to synovial sarcomas at more conventional sites, this is a disease of 
young adults: ages ranging from 16-49 years (median 34 years) (Shmookler et al., 1982). It 
has been reported that synovial sarcoma of the head and neck is seen most commonly in 
patients who are more than a decade younger than patients who have the same neoplasm in 
the trunk and extremities (Miloro et al., 1994). To the best of our knowledge, this is the 
youngest recorded patient with synovial sarcoma of the parotid gland. 
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Salivary gland tumours are rare in children (Zernial et al., 2007). Primary synovial sarcoma 
of the parotid gland is a rare occurrence that may commonly cause differential diagnostic 
difficulties (Barkan and El-Naggar, 2004). A painless neck mass was the single most 
common presenting symptom (Amble et al., 1992). The diagnosis of synovial sarcoma 
proved difficult and approximately one third of the patients initially received incorrect 
pathologic diagnosis. Synovial sarcoma is a mesenchymal spindle cell tumour, which may 
display variable epithelial differentiation. It may present as biphasic or monophasic variant. 
Biphasic SS has epithelial and spindle cell components in varying proportions, and in 
monophasic SS the spindle cell component often occurs alone (Fisher, 1998). Shmookler et 
al. (1982) stressed that differential diagnosis, depending on the proportion of the biphasic 
components, ranged from spindle cell mesenchymal neoplasms to various 
adenocarcinomas, including those arising in mixed tumours of the salivary gland. In the 
parotid gland, it is most likely to be misdiagnosed as a myoepithelial, primary 
mesenchymal, or metastatic neoplasm (Jay et al., 2008). The criteria for establishing a 
primary salivary gland origin are: (1) the patient must not have, or have had, a sarcoma in 
another site; (2) patient evaluation has excluded the likelihood of metastatic disease; (3) the 
gross and microscopic appearances support primary origin rather than invasion from 
adjacent soft tissue, and (4) carcinosarcoma has been excluded (Ellis and Auclair, 1996). In 
our case, the tumour was monophasic. Epithelial differentiation could not be confirmed 
even by immunostaining. Although even monophasic SS can sometimes reveal an epithelial 
component, this is not necessary for diagnosis. Sensitive immunohistochemical markers for 
neoplastic myoepithelium, such as calponin, S-100 protein and smooth muscle actin are not 
specific for myoepithelial carcinoma since numerous normal and neoplastic cells, including 
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spindle cells in synovial sarcoma, may express reactivity for these markers (Ellis and 
Auclair, 2008). In general, age of the patient, histological pattern of the tumour, lack of the 
epithelial component and, most important, molecular demonstration of the characteristic 
translocations excluded carcinosarcoma and myoepithelial carcinoma, and were definitive 
for monophasic variant of synovial sarcoma as a final diagnosis. 
During preoperative analysis of our patient we performed an FNA biopsy, which suggested 
tumour of mesenchymal origin. Analysis pointed to a tumour of mesenchymal origin, 
which was one of the important criteria for our differential diagnosis and the planning of 
therapy. Radiographic findings (CT or MR imaging) are helpful in defining the location and 
extent of the neoplasm and may, at times, even suggest the correct diagnosis. Because the 
appearance of synovial sarcomas varies and other nonmucosal head and neck masses may 
appear similar, no specific imaging characteristics define the entity (Hirsch et al., 1997). 
Due to the rarity of this neoplasm in the head and neck region, information regarding 
appropriate therapy for this neoplasm is limited. We performed a complete surgical 
resection (total parotidectomy) with an elective neck dissection of levels II, III and Va, 
postoperative chemotherapy and radiotherapy. Many authors agree that tumour size is the 
most important prognostic factor (Fisher, 1998; Wang et al., 2008). Thompson et al. (2000) 
stressed that patients with tumours with a widest diameter greater than 5 cm have a poorer 
prognosis than those with tumours less than 5 cm in diameter. Also, the authors urge that a 
multicenter trial for neoadjuvant chemotherapy should be initiated for patients presenting 
with a synovial sarcoma greater than 10 cm in diameter (Thompson et al., 2000). 
Metastases are not frequent at diagnosis, but distant metastases remain a predominant cause 
of death. The most common site of distant metastasis is the lung (97%) and it may occur 
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years after initial therapy, with an average duration from initial treatment to detection of 
30.8 months (Amble et al., 1992; Goebel et al., 2004). The article by Lee and Shin (2008) 
from Memorial Sloan-Kettering Cancer Center highlights the importance of a 
multidisciplinary approach in the treatment of this disease. Harb et al. (2007) stressed that 
survival rates were associated with tumour location, size, and extension. Giaoui et al. 
(1999) say that favourable prognostic findings include age less than 20 years and complete 
initial resection. Post treatment recurrence rate for synovial sarcoma arising from all body 
sites is 50%, most cases recur in the first two years after treatment (Fisher, 1998). Follow-
up of patients with synovial sarcoma of the head and neck indicate that 21-44% will 
develop local recurrence and 24-48% distant metastases (especially to the lung), with an 
overall 5-year survival of 47-58% (Barnes, 2001). However, some authors have shown 5 
year survival rates of up to 65-70% (Ladenstein et al., 1993) while other authors emphasize 
that despite a five year survival rate of 25-50%, the 10 year survival rate is only 10-15% 
(Sun et al., 2003). One other report describes that prognosis for patients with synovial 
sarcoma in the head and neck is better than for patients with synovial sarcoma in the trunk 
and extremities because this tumour in the head and neck presents in younger patients and 
is treated earlier after the onset of symptoms (Hirsch et al., 1997). 
Besauese of low reported incidence there is a global lack of experience in dealing with 
synovial sarcoma of the head and neck. Kartha and Bumpous (2002) stressed a more 
aggressive behaviour of the synovial sarcoma of the head and neck than of the same 
neoplasm in the extremities. Because of the aggressive nature of synovial sarcoma, some 
modification of accepted treatment modalities may be required. Most authors agree that 
adequate primary surgery is essential to both local control and overall outcome for synovial 
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sarcoma patients (Bergh et al., 1999). Some of them propose that a neck dissection is not 
warranted, because only 3-4% of synovial sarcoma of head and neck are associated with 
cervical lymph node metastasis (Shmookler et al., 1982; Amble et al., 1992). One other 
report has shown that twenty-five percent of the cases involve regional lymph nodes 
(Tilakaratne, 2006). Moreover, lymph node metastases develop more frequently than in 
other nonrhabdomyosarcoma soft tissue sarcomas (Ferrari et al., 1999). In our opinion the 
surgical procedure would be radical excision with some type of elective neck dissection 
because at the time of operation we didn't know true histological diagnosis. Frozen section 
analysis hasn't been done, because it wouldn't change the extent of surgical treatment. 
However, in most instances at the time of surgery histopathological diagnosis is unknown. 
The only guidance is clinical appearance and the fine needle biopsy. 
A number of authors report diverse opinions concerning the value of radiation therapy and 
chemotherapy in treatment of synovial sarcoma in the head and neck region (Goebel et al., 
2004; Ferrari et al., 1999). Amble et al. (1992) proposed wide local excision with 
postoperative radiotherapy of 65 Gy and considered prophylactic neck dissection and 
chemotherapy to be less effective. Synovial sarcoma is often chemosensitive, and given its 
poor prognosis, multicenter trials of adjuvant therapy are warranted (Spillane et al., 2000). 
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CONCLUSION 
 
The primary synovial sarcoma of the parotid gland is extremely rare, especially in children. 
Two years after therapy our young patient is well with no evidence of disease. That is a 
short follow-up period, but we can say that multimodal therapy with aggressive surgical 
excision followed by early postoperative chemotherapy and radiotherapy can be a 
promising factor. 
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FIGURE LEGENDS  
 
FIGURE (1) MRI axial image (native) showing multinodular well demarcated mass 
occupying right parotid gland 
 
 
FIGURE (2) MRI coronal image (with contrast) 
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FIGURE (3) Surgical specimen including wide excision and total parotidectomy with 
selective neck dissection (levels II, III and Va) 
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FIGURE (4) The tumour within parotid gland composed of highly cellular whirling 
fascicles of spindle-shaped cells with indistinct cytoplasms (haematoxylin-eosin stain, 
original magnification x 100) 
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FIGURE (5) Diffusely and strongly positive bcl-2 immunostaining 
 
